AU2005231769A1 - A method of treatment for stroke employing administration of defibrinogenating agents to achieve a specific defibrinogenation pattern - Google Patents

A method of treatment for stroke employing administration of defibrinogenating agents to achieve a specific defibrinogenation pattern Download PDF

Info

Publication number
AU2005231769A1
AU2005231769A1 AU2005231769A AU2005231769A AU2005231769A1 AU 2005231769 A1 AU2005231769 A1 AU 2005231769A1 AU 2005231769 A AU2005231769 A AU 2005231769A AU 2005231769 A AU2005231769 A AU 2005231769A AU 2005231769 A1 AU2005231769 A1 AU 2005231769A1
Authority
AU
Australia
Prior art keywords
ancrod
stroke
treatment
defibrinogenation
fibrinogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2005231769A
Other languages
English (en)
Inventor
Samn Raffaniello Petti
Stephen J. Petti
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Neurobiological Technologies Inc
Original Assignee
SAMN PETTI
STEPHEN PETTI
Neurobiological Technologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SAMN PETTI, STEPHEN PETTI, Neurobiological Technologies Inc filed Critical SAMN PETTI
Publication of AU2005231769A1 publication Critical patent/AU2005231769A1/en
Assigned to NEUROBIOLOGICAL TECHNOLOGIES, INC. reassignment NEUROBIOLOGICAL TECHNOLOGIES, INC. Request for Assignment Assignors: NEUROBIOLOGICAL TECHNOLOGIES, INC., Samn, Petti, Stephen, Petti
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AU2005231769A 2004-03-30 2005-03-30 A method of treatment for stroke employing administration of defibrinogenating agents to achieve a specific defibrinogenation pattern Abandoned AU2005231769A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10/812,510 US20050220782A1 (en) 2004-03-30 2004-03-30 Method of treatment for stroke employing administration of defibrinogenating agents to achieve a specific defibrinogenation pattern
US10/812,510 2004-03-30
PCT/US2005/010769 WO2005097262A1 (en) 2004-03-30 2005-03-30 A method of treatment for stroke employing administration of defibrinogenating agents to achieve a specific defibrinogenation pattern

Publications (1)

Publication Number Publication Date
AU2005231769A1 true AU2005231769A1 (en) 2005-10-20

Family

ID=34964955

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2005231769A Abandoned AU2005231769A1 (en) 2004-03-30 2005-03-30 A method of treatment for stroke employing administration of defibrinogenating agents to achieve a specific defibrinogenation pattern

Country Status (8)

Country Link
US (1) US20050220782A1 (https=)
EP (1) EP1740271A1 (https=)
JP (1) JP2007531759A (https=)
AU (1) AU2005231769A1 (https=)
CA (1) CA2561645A1 (https=)
IL (1) IL178426A0 (https=)
RU (1) RU2006138043A (https=)
WO (1) WO2005097262A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102016110642A1 (de) * 2016-06-09 2017-12-14 Nordmark Holding Gmbh Verwendung von Ancrod zur Vorbeugung und/oder Behandlung von Ischämie

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5523292A (en) * 1992-10-14 1996-06-04 Schwartz; Robert Method of preventing restenosis following coronary angioplasty
US6165795A (en) * 1998-06-25 2000-12-26 Cardiovascular Diagnostics, Inc. Methods for performing fibrinogen assays using dry chemical reagents containing ecarin and magnetic particles

Also Published As

Publication number Publication date
CA2561645A1 (en) 2005-10-20
IL178426A0 (en) 2007-02-11
RU2006138043A (ru) 2008-05-10
JP2007531759A (ja) 2007-11-08
US20050220782A1 (en) 2005-10-06
WO2005097262A1 (en) 2005-10-20
EP1740271A1 (en) 2007-01-10

Similar Documents

Publication Publication Date Title
US5180583A (en) Method for the treatment of bleeding disorders
CA1281647C (en) Compositions and methods for the treatment of bleeding disorders
JP3805981B2 (ja) 凝固亢進状態または後天性プロテインｃ欠乏症を処置する方法
DE3855096T2 (de) Hemmung von arteriellem thrombotischen Verschluss oder von Thrombo-Embolismus
CN1090029C (zh) 溶血栓活性蛋白和抗凝血剂的组合物及其应用
Woessner et al. Influence of a long-term, high-dose volume therapy with 6% hydroxyethyl starch 130/0.4 or crystalloid solution on hemodynamics, rheology and hemostasis in patients with acute ischemic stroke: Results of a randomized, placebo-controlled, double-blind study
WO1998058661A1 (en) Use of fviia for the treatment of bleedings in patients with a normal blood clotting cascade and normal platelet function
Mariani et al. Treatment of congenital factor VII deficiency with a new concentrate
Eisenberg Role of heparin in coronary thrombolysis
US5690931A (en) Method for treating thromboembolic conditions via the use of multiple bolus administration of thrombolytically active proteins
Kakkar et al. 4 Prevention of venous thromboembolism in general surgery
US20050220782A1 (en) Method of treatment for stroke employing administration of defibrinogenating agents to achieve a specific defibrinogenation pattern
Köhler et al. High-dose systemic streptokinase and acylated streptokinase-plasminogen complex (BRL 26921) in acute myocardial infarction: alterations of the fibrinolytic system and clearance of fibrinolytic activity
EP1133314B1 (en) Protein c for the treatment of sickle cell disease and thalassemia
US5342616A (en) Method of administering tissue plasminogen activator
Bell et al. Isotopic studies of therapeutic anticoagulation with a coagulating enzyme
Huet et al. Low Molecular Weight Heparin Fraction PK10169: A New Therapeutic Means for Anticoagulant Therapy?
Ezer et al. Neonatal purpura fulminans due to homozygous protein C deficiency
Mola et al. A pilot study of pro-urokinase in the treatment of deep vein thrombosis
Sagripanti et al. Iloprost in the treatment of thrombotic microangiopathy: report of thirteen cases
Liu‐DeRyke et al. Hemostatic therapy for the treatment of intracranial hemorrhage
Huet et al. Treatment of acute pulmonary embolism by a low molecular weight heparin fraction. A preliminary study
JP2783367B2 (ja) ヘパリン含有製剤
EP0352897B1 (en) Tpa-containing medicaments
EP0733371B1 (de) Mittel zur subkutanen Verabreichung von Protein C

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: NEUROBIOLOGICAL TECHNOLOGIES, INC.

Free format text: FORMER APPLICANT(S): NEUROBIOLOGICAL TECHNOLOGIES, INC.; STEPHEN, PETTI; SAMN, PETTI

MK1 Application lapsed section 142(2)(a) - no request for examination in relevant period